Loading...
•
Mar 31, 2024
Ionis Q1 2024 Earnings Report
Ionis reported financial results for Q1 2024, highlighting the WAINUA launch and progress in regulatory submissions and clinical data.
Key Takeaways
Ionis Pharmaceuticals reported its Q1 2024 financial results, featuring total revenues of $119 million. The company saw increased operating expenses due to investments in launching WAINUA, olezarsen, and donidalorsen. They reaffirmed their 2024 financial guidance and have $2.2 billion in cash and short-term investments.
WAINUA launch is progressing well, contributing $1 million in royalty revenue.
Olezarsen NDA was submitted to the FDA for FCS, with EU regulatory submission preparation underway.
Positive Phase 3 donidalorsen data for HAE were reported, with regulatory submissions being prepared.
Ionis is on track to achieve its 2024 financial guidance.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comWAINUA royalties Revenue
CapyFin.comOther royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.comCollaborative agreements Revenue
CapyFin.comWAINUA joint dev. Revenue
CapyFin.com Forward Guidance
Ionis reaffirmed its 2024 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income